Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance

Robert A. Campbell, Poornima Bhat-Nakshatri, Nikhil M. Patel, Demetra Constantinidou, Simak Ali, Harikrishna Nakshatri

Research output: Contribution to journalArticle

742 Citations (Scopus)

Abstract

Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions. Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes. However, anti-estrogen-resistant growth of ER-positive tumors remains a significant clinical problem. Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen. Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1. PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα. The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT. In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo. Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1. We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis. Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.

Original languageEnglish
Pages (from-to)9817-9824
Number of pages8
JournalJournal of Biological Chemistry
Volume276
Issue number13
DOIs
StatePublished - Mar 30 2001

Fingerprint

Phosphatidylinositol 3-Kinase
Estrogen Receptors
Estrogens
Chemical activation
Phosphorylation
Tamoxifen
Genes
Growth Differentiation Factor 15
Breast Neoplasms
bcl-2 Genes
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Response Elements
Growth
Genetic Promoter Regions
Tumors
Proteins
Breast
Up-Regulation
Epithelial Cells
Cells

ASJC Scopus subject areas

  • Biochemistry

Cite this

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α : A new model for anti-estrogen resistance. / Campbell, Robert A.; Bhat-Nakshatri, Poornima; Patel, Nikhil M.; Constantinidou, Demetra; Ali, Simak; Nakshatri, Harikrishna.

In: Journal of Biological Chemistry, Vol. 276, No. 13, 30.03.2001, p. 9817-9824.

Research output: Contribution to journalArticle

Campbell, Robert A. ; Bhat-Nakshatri, Poornima ; Patel, Nikhil M. ; Constantinidou, Demetra ; Ali, Simak ; Nakshatri, Harikrishna. / Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α : A new model for anti-estrogen resistance. In: Journal of Biological Chemistry. 2001 ; Vol. 276, No. 13. pp. 9817-9824.
@article{e508dc3976804e41ac7571c3f2122f5d,
title = "Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance",
abstract = "Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions. Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes. However, anti-estrogen-resistant growth of ER-positive tumors remains a significant clinical problem. Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen. Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1. PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα. The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT. In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo. Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1. We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis. Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.",
author = "Campbell, {Robert A.} and Poornima Bhat-Nakshatri and Patel, {Nikhil M.} and Demetra Constantinidou and Simak Ali and Harikrishna Nakshatri",
year = "2001",
month = "3",
day = "30",
doi = "10.1074/jbc.M010840200",
language = "English",
volume = "276",
pages = "9817--9824",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α

T2 - A new model for anti-estrogen resistance

AU - Campbell, Robert A.

AU - Bhat-Nakshatri, Poornima

AU - Patel, Nikhil M.

AU - Constantinidou, Demetra

AU - Ali, Simak

AU - Nakshatri, Harikrishna

PY - 2001/3/30

Y1 - 2001/3/30

N2 - Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions. Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes. However, anti-estrogen-resistant growth of ER-positive tumors remains a significant clinical problem. Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen. Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1. PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα. The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT. In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo. Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1. We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis. Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.

AB - Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions. Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes. However, anti-estrogen-resistant growth of ER-positive tumors remains a significant clinical problem. Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen. Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1. PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα. The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT. In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo. Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1. We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis. Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.

UR - http://www.scopus.com/inward/record.url?scp=0035971181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035971181&partnerID=8YFLogxK

U2 - 10.1074/jbc.M010840200

DO - 10.1074/jbc.M010840200

M3 - Article

C2 - 11139588

AN - SCOPUS:0035971181

VL - 276

SP - 9817

EP - 9824

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -